Research graph
References from Three versus six weeks of corticosteroids for mild immune-related pneumonitis: a randomized trial. Local targets link to admitted publications; unresolved targets remain external evidence.
Combined nivolumab and ipilimumab or monotherapy in untreated melanoma
10.1056/nejmoa1504030 · 2015 · External reference
Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer
10.1056/nejmoa1810865 · 2018 · External reference
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
10.1016/s0140-6736(19)32591-7 · 2019 · External reference
Immune checkpoint inhibitors in 10 years: contribution of basic research and clinical application in cancer immunotherapy
10.4110/in.2022.22.e2 · 2022 · External reference
Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update
10.1200/jco.21.01440 · 2021 · External reference
Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
10.1016/j.annonc.2022.10.001 · 2022 · External reference
Immune checkpoint inhibitor-related pneumonitis in lung cancer: real-world incidence, risk factors, and management practices across six health care centers in North Carolina
10.1016/j.chest.2021.02.032 · 2021 · External reference
Immune-checkpoint inhibitors: long-term implications of toxicity
10.1038/s41571-022-00600-w · 2022 · External reference
Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy
10.1200/jco.2016.68.2005 · 2017 · External reference
Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis
10.1001/jamaoncol.2016.2453 · 2016 · External reference
A real-world study on the effectiveness and safety of pembrolizumab plus chemotherapy for nonsquamous NSCLC
10.1016/j.jtocrr.2021.100265 · 2022 · External reference
Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort study
10.1136/jitc-2022-004670 · 2022 · External reference
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
10.1136/jitc-2021-002435 · 2021 · External reference
Pneumonitis associated with pembrolizumab plus chemotherapy for non-squamous non-small cell lung cancer
10.1038/s41598-023-30676-y · 2023 · External reference
Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis
10.1056/nejmoa1803537 · 2020 · External reference
Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study
10.1136/bmj.j1415 · 2017 · External reference
Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer
10.1200/jco.2018.79.0006 · 2018 · External reference
Better late than never: the impact of steroidal treatment on the outcome of melanoma patients treated with immunotherapy
10.3390/cancers15113041 · 2023 · External reference
Early use of high-dose glucocorticoid for the management of irAE is associated with poorer survival in patients with advanced melanoma treated with anti-PD-1 monotherapy
10.1158/1078-0432.ccr-21-1283 · 2021 · External reference
Negative association of steroids with immunotherapy efficacy in a multi-tumor cohort: time and dose-dependent
10.1007/s00262-024-03772-9 · 2024 · External reference
Chest CT diagnosis and clinical management of drug-related pneumonitis in patients receiving molecular targeting agents and immune checkpoint inhibitors: a position paper from the Fleischner Society
10.1016/j.chest.2020.11.027 · 2021 · External reference
The development and validation of the King’s Brief Interstitial Lung Disease (K-BILD) health status questionnaire
10.1136/thoraxjnl-2012-201581 · 2012 · External reference
King’s Brief Interstitial Lung Disease questionnaire: responsiveness and minimum clinically important difference
10.1183/13993003.00281-2019 · 2019 · External reference
Nintedanib in progressive fibrosing interstitial lung diseases
10.1056/nejmoa1908681 · 2019 · External reference
The King’s Brief Interstitial Lung Disease (KBILD) questionnaire: an updated minimal clinically important difference
10.1136/bmjresp-2018-000363 · 2019 · External reference
Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes
10.1136/jitc-2020-001731 · 2021 · External reference
